Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors
Peptide receptor radionuclide therapy (PRRT) is an established treatment in advanced neuroendocrine tumors (NETs), which overexpressed somatostatin receptors. However, after progression there are a limited number of available treatments. We want to share a case report about a patient with a NET re-t...
Main Authors: | Elena María Vida Navas, Alberto Martínez Lorca, Aintzane Sancho Gutiérrez, Lucia Sanz Gómez, Teresa Navarro Martínez, Enrique Grande Pulido, Alfredo Carrato Mena, Pablo Gajate Borau |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2021.676973/full |
Similar Items
-
177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites
by: Pradeep Thapa, et al.
Published: (2017-01-01) -
Evaluation of Kidney Dose in Neuroendocrine Tumors Patients after Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE
by: N.R. Hidayati, et al.
Published: (2019-12-01) -
A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
by: Pashtoon Murtaza Kasi, et al.
Published: (2019-01-01) -
Peptide receptor radionuclide therapy with 177Lu-DOTATATE for metastatic neuroendocrine tumor occurring in association with multiple endocrine neoplasia type 1 and cushing's syndrome
by: Chinna Naik, et al.
Published: (2017-01-01) -
Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE
by: Olof Joakim Pettersson, et al.
Published: (2021-04-01)